TransEnterix Receives CE Mark for Machine Vision System in Robotic Surgery
19 Enero 2021 - 5:55AM
Business Wire
The Intelligent Surgical UnitTM Enables
Augmented Intelligence on the SenhanceⓇ Surgical System
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
the Company received CE Mark approval for the Intelligent Surgical
UnitTM (ISUTM) that enables machine vision capabilities on the
SenhanceⓇ Surgical System. This approval will provide Senhance
digital laparoscopic programs in Europe access to this new
technology, ushering them to the forefront of surgical innovation
utilizing augmented intelligence.
“Augmented intelligence powered by machine vision will be one of
the primary drivers in transforming surgery to enhance the
capabilities of surgeons,” said Anthony Fernando, TransEnterix
president and CEO. “We have already successfully implemented
augmented intelligence in the U.S. with the Senhance System after
receiving FDA clearance last year. We are pleased to expand this
important capability to our broader global user base."
For the first time in surgery, the ISU’s machine vision
capabilities provide the ability to recognize certain objects and
locations in the surgical field. This new capability enhances
visualization and camera control over currently available surgical
technologies, and provides the foundation for additional augmented
intelligence capabilities. Additionally, the ISU improves surgical
team collaboration by seamlessly sharing the surgeon’s console view
in real-time across the entire operating room. Future augmented
intelligence features may include 3D point-to-point measurement and
anatomical structure identification, further enhancing the digital
laparoscopic experience with Senhance.
“Real-time augmented intelligence is a powerful new capability
made possible by digitizing surgery,” said Dr. Amit Trivedi, chair
of surgery at Hackensack Meridian Health Pascack Valley Medical
Center and the first surgeon to utilize the ISU in augmented
surgery with Senhance. “I’ve been able to benefit from the new
capabilities of the Senhance System in over 40 surgeries, to
seamlessly move the camera to specific points in the surgical field
and track with my instruments as I perform delicate tasks. This new
technology is interpreting and analyzing information from the
surgery, and the additional possibilities of this platform are very
exciting.”
This Intelligent Surgical Unit is compatible with both the
global installed base of Senhance Surgical Systems and with
third-party vision systems that are currently supported by
Senhance.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance® Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, Russia, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and the Company receiving CE Mark approval for its
Intelligent Surgical Unit (ISU) that enables machine vision
capabilities on the Senhance Surgical System. These statements and
other statements regarding our future plans and goals constitute
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the ISU approval will provide
Senhance digital laparoscopic programs in Europe access to this new
technology, ushering them to the forefront of surgical innovation
utilizing augmented intelligence and whether augmented intelligence
powered by machine vision will be one of the primary drivers in
transforming surgery to enhance the capabilities of surgeons. For a
discussion of the risks and uncertainties associated with
TransEnterix's business, please review our filings with the
Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K for the year ended December 31, 2019, filed
with the SEC on March 16, 2020 and our other filings we make with
the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as
of the date of this press release and speak only as of the
origination date of this press release. We undertake no obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005296/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024